AKT and EZH2 Inhibition Co-opts Mammary Gland Involution to Target TNBC

Major Finding: AKT and EZH2 inhibitors synergistically induce apoptosis and regression in triple negative breast cancer (TNBC).
Concept: The combination drives luminal differentiation that sensitizes TNBC to involution-associated cell death.
Impact: This study proposes the potential clinical benefit of an AKT/EZH2-targeted therapeutic strategy in TNBC.